Antibacterial polypeptide as well as preparation method and application thereof
By designing the peptide sequence to adjust the amino acid distribution and three-dimensional structure, the problem of insufficient antibacterial activity and toxicity of antibacterial peptides on Pseudomonas aeruginosa and Candida albicans is solved, effectively inhibiting and bactericidal effects on both, and reducing the effect of toxicity of cells, high biocompatibility and low drug resistance risk.
Patent Information
- Application Number
- CN202410922460.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-10
AI Technical Summary
The existing antibacterial polypeptides have low antibacterial activity against Pseudomonas aeruginosa and Candida albicans, and are partially toxic to eukaryotes, resulting in drug resistance and toxicity problems in treatment.
By designing the peptide sequence, adjusting the distribution of basic and hydrophobic amino acids, increasing tryptophan to improve hydrophobicity, and using arginine to provide a positive charge targeting bacterial membranes, synergistically to improve targeting Candida albicans , proline enhances bioselectivity and prepares antibacterial polypeptides with intermediate helical and bilateral circle three-dimensional structures.
It has achieved good inhibitory and bactericidal effects on Pseudomonas aeruginosa and Candida albicans, and has no toxic side effects on cells, has good biocompatibility, and reduces the risk of drug resistance.
Smart Images

Figure BDA0004937110060000061 
Figure BDA0004937110060000081 
Figure HDA0004937110070000011
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to an antibacterial polypeptide, its preparation method, and its application. Background Technology
[0002] The overuse of antibiotics has led to the emergence of many drug-resistant and resistant bacteria, complicating treatment. Antimicrobial peptides, also known as host defense peptides, have attracted increasing attention from scientists worldwide in recent years and are considered a promising next-generation antimicrobial drug. Compared to traditional antibiotics, most pathogenic bacteria exhibit almost no resistance to antimicrobial peptides. However, most natural antimicrobial peptides have low antimicrobial activity, and some can be toxic to eukaryotes. Therefore, research on modifying antimicrobial peptides to increase their antimicrobial properties and reduce their toxicity has become a hot topic and a trend. Summary of the Invention
[0003] The present invention aims to at least solve one of the technical problems existing in the prior art. To this end, the present invention proposes a polypeptide that exhibits good antibacterial activity against Pseudomonas aeruginosa and Candida albicans.
[0004] The present invention also proposes a method for preparing the above-mentioned polypeptide.
[0005] The present invention also proposes applications of the above-mentioned polypeptides.
[0006] The present invention also proposes a drug.
[0007] According to one aspect of the invention, a polypeptide is provided, said polypeptide being selected from any one of the following (1)-(4):
[0008] (1) A polypeptide having an amino acid sequence such as SEQ ID NO:1;
[0009] (2) A polypeptide having an amino acid sequence such as SEQ ID NO:2;
[0010] (3) A polypeptide with the same function as the polypeptide shown in (1) is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO:1.
[0011] (4) A polypeptide having the same function as the polypeptide shown in (2) is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO:2.
[0012] The polypeptide of this invention is obtained by changing or replacing the positions of amino acid residues on the spiral projection diagram, so that basic amino acid residues are distributed on one side and hydrophobic amino acids are distributed on the other side. At the same time, tryptophan is added to improve the hydrophobicity of the bactericidal effect, arginine provides positive charge to target the bacterial membrane, and the targeting effect of the polypeptide on Candida albicans is improved through the synergistic effect of tryptophan and lysine. Proline is used to enhance the biological selectivity, and finally the polypeptide sequence of this application is determined.
[0013] In some embodiments of the present invention, the antimicrobial peptide has a three-dimensional structure with a central helical shape and two coiled ends.
[0014] According to a second aspect of the invention, a biomaterial is provided, said biomaterial being any one of 1) to 4):
[0015] 1) The nucleic acid molecule encoding the above-mentioned polypeptide;
[0016] 2) An expression cassette containing the nucleic acid molecule described in 1);
[0017] 3) A recombinant vector containing the nucleic acid molecule described in 1) or the expression cassette described in 2);
[0018] 4) Recombinant cells containing the nucleic acid molecule described in 1), the expression cassette described in 2), or the recombinant vector described in 3).
[0019] A second aspect of the present invention provides a method for preparing the above-mentioned polypeptide, the method comprising the following steps: using a solid-phase synthetic resin as a starting material, the polypeptide is prepared by a solid-phase synthesis method.
[0020] In some embodiments of the present invention, the antimicrobial peptide can also be synthesized artificially.
[0021] In some embodiments of the present invention, the preparation of the antimicrobial peptide is carried out sequentially from the C-terminus to the N-terminus.
[0022] In some embodiments of the present invention, the solid-phase synthetic resin includes Rink resin.
[0023] In some embodiments of the present invention, the method further includes the step of immersing the solid-phase synthetic resin in a DMF solution to cause it to swell.
[0024] In some embodiments of the present invention, the solid-phase synthetic resin is immersed in DMF solution for 30-50 minutes.
[0025] In some embodiments of the present invention, the solid-phase synthesis method includes attaching an amino acid containing a protecting group to a resin, and sequentially performing washing, deprotection, and coupling steps until the last amino acid is grafted to obtain a polypeptide chain; after sequentially deprotecting and washing the polypeptide chain, it is cleaved to obtain the polypeptide.
[0026] In some embodiments of the present invention, the protecting group includes Fmoc-.
[0027] In some embodiments of the present invention, amino acids containing protecting groups are attached to the resin, and the activators used include 0.3-0.5M HBTU and 1-3M DIEA.
[0028] In some embodiments of the present invention, the rinsing agent includes DMF.
[0029] In some embodiments of the present invention, the deprotection includes adding a piperidine deprotection solution with a mass fraction of 15%-25%, reacting, removing the liquid phase, and cleaning the resin.
[0030] In some embodiments of the present invention, the cleaning resin uses DMF as a reagent.
[0031] In some embodiments of the present invention, the coupling includes the step of dissolving the deprotected resin and then adding a mixture of HBTU and amino acids to carry out the reaction.
[0032] In some embodiments of the present invention, the concentration of HBTU is 0.3-0.5M.
[0033] In some embodiments of the present invention, the preparation of the amino acid mixture includes: activating the amino acid solution by introducing nitrogen gas, and then adding a 1-3M DIEA solution to react.
[0034] In some embodiments of the present invention, the washing liquid used for washing includes at least one of DMF, methanol and dichloromethane.
[0035] In some embodiments of the present invention, the cutting is performed using a cutting fluid.
[0036] In some embodiments of the present invention, the cutting fluid comprises the following components: TFA, Tis, EDT, anisole sulfide, and phenol.
[0037] In some embodiments of the present invention, the step of washing the polypeptide with diethyl ether is also included.
[0038] In some embodiments of the present invention, the temperature of the diethyl ether is 0-8°C.
[0039] According to a fourth aspect of the present invention, the application of the above-mentioned polypeptides or biomaterials in the preparation of antibacterial products is proposed.
[0040] In some embodiments of the present invention, the bacteria include bacteria and fungi.
[0041] In some embodiments of the present invention, the bacteria include Gram-negative bacteria.
[0042] In some embodiments of the present invention, the Gram-negative bacteria include Pseudomonas aeruginosa.
[0043] In some embodiments of the present invention, the fungus includes Candida albicans.
[0044] In some embodiments of the present invention, the product includes a drug or formulation.
[0045] According to a fifth aspect of the present invention, a medicament is provided, the medicament comprising the above-described polypeptide.
[0046] In some embodiments of the present invention, the drug has antibacterial activity.
[0047] In some embodiments of the present invention, the drug further includes a pharmaceutical carrier.
[0048] In some embodiments of the present invention, the pharmaceutical carrier is a conventional drug carrier in the pharmaceutical field. In some embodiments of the present invention, the pharmaceutical carrier includes at least one selected from diluents, excipients, fillers, binders, disintegrants, absorption enhancers, surfactants, adsorbents, lubricants, sweeteners, and flavorings.
[0049] In some embodiments of the invention, the excipient comprises water.
[0050] In some embodiments of the present invention, the filler includes at least one of starch and sucrose.
[0051] In some embodiments of the present invention, the adhesive includes at least one of cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone.
[0052] In some embodiments of the present invention, the wetting agent includes glycerin.
[0053] In some embodiments of the present invention, the disintegrant includes at least one of agar, calcium carbonate, and sodium bicarbonate.
[0054] In some embodiments of the present invention, the absorption enhancer includes a quaternary ammonium compound.
[0055] In some embodiments of the present invention, the surfactant includes hexadecyl alcohol.
[0056] In some embodiments of the present invention, the adsorbent carrier includes at least one of kaolin and soap clay.
[0057] In some embodiments of the present invention, the lubricant includes at least one of talc, calcium stearate, magnesium stearate, and polyethylene glycol.
[0058] In some embodiments of the present invention, the polypeptide has a mass fraction of 0.01% to 99% in the drug.
[0059] According to some preferred embodiments of the present invention, the polypeptide has a mass fraction of 0.05% to 95% in the drug.
[0060] According to some preferred embodiments of the present invention, the polypeptide has a mass fraction of 0.05% to 20% in the drug.
[0061] In some embodiments of the present invention, the dosage form of the drug is a variety of dosage forms conventional in the art, preferably in the form of a solid, semi-solid or liquid, and may be an aqueous solution, a non-aqueous solution or a suspension, more preferably a tablet, capsule, soft capsule, granule, pill, oral liquid, dry suspension, drop pill, dry extract, injection or infusion, transdermal agent, or transdermal microneedle.
[0062] In some embodiments of the present invention, the administration method of the drug may be a conventional administration method in the art, including but not limited to injection or oral administration.
[0063] The injection administration can be administered via intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection, or subcutaneous injection.
[0064] According to some embodiments of the present invention, at least the following beneficial effects are achieved: The antimicrobial peptides prepared by the present invention, through the rational configuration of basic amino acid, hydrophobic amino acid, tryptophan, and other sites, exhibit good inhibitory and bactericidal effects against Pseudomonas aeruginosa and Candida albicans. Simultaneously, the designed antimicrobial peptide L18N6P has no toxic side effects on cells and can even promote the proliferation of human dermal fibroblasts, exhibiting excellent biocompatibility. It has the potential to become a drug for treating Pseudomonas aeruginosa or Candida albicans infections or a material for preparing antimicrobial medical devices, and is less prone to drug resistance, thus possessing high application value. Attached Figure Description
[0065] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0066] Figure 1 This is a helical projection diagram of polypeptide L18N5 in Example 1 of the present invention;
[0067] Figure 2 This is a projection view of the helical wheel of L18N6P in Embodiment 1 of the present invention;
[0068] Figure 3 This is a three-dimensional structural diagram of polypeptide L18N5 in Example 1 of the present invention;
[0069] Figure 4 This is a three-dimensional structural diagram of the polypeptide L18N6P in Example 1 of the present invention;
[0070] Figure 5 This is a reversed-phase high-performance liquid chromatography (RP-HPLC) detection result of polypeptide L18N5 in Example 1 of the present invention;
[0071] Figure 6 This is a reversed-phase high-performance liquid chromatography (RP-HPLC) detection result of polypeptide L18N6P in Example 1 of the present invention.
[0072] Figure 7 This is a graph showing the effect of different polypeptides on cell activity in Example 1 of the present invention;
[0073] Figure 8 This is a cell morphology diagram observed after staining of live and dead cells in Example 1 of the present invention, wherein the scale bar is 100 μm. Detailed Implementation
[0074] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.
[0075] Example 1
[0076] This embodiment prepares an antibacterial polypeptide, and the specific process is as follows:
[0077] 1. Design of antimicrobial peptides
[0078] By selecting hydrophobic amino acids (leucine, alanine, phenylalanine) and basic amino acids (arginine, lysine), and adjusting and replacing the sites of specific amino acids on the polypeptide helix, the hydrophobicity of the polypeptide was adjusted so that the hydrophobic amino acids were distributed on one side of the final helix, and the basic amino acids were distributed on the other side. The distribution sites of arginine, tryptophan, lysine, etc., were rationally configured, and the polypeptide L18N5 was designed. By replacing Glycine in L18N5... 1 Gly 4 For Leu 1 Val 4 Arg 2Arg 3 Arg 17 Replace with Lys 2 Lys 3 Lys 17 Ala 18 Replace with Pro 18 The polypeptide L18N6P was obtained, and the sequences and physicochemical parameters of the two polypeptides are shown in Table 1.
[0079] Table 1. Sequences and physicochemical parameters of antimicrobial peptides
[0080]
[0081] a Average hydrophobicity was calculated using HeliQuest.
[0082] b Hydrophobic torque was calculated using HeliQuest analysis.
[0083] HeliQuest was used to predict the performance and helical wheel projection diagrams of peptides L18N5 and L18N6P, as shown below. Figure 1 , 2 As shown, lysine and arginine residues are distributed on the same side of the spiral wheel projection diagram, while other amino acids are distributed on the other side.
[0084] The three-dimensional conformation of peptides was predicted using the online structure prediction software I-TASSER. The three-dimensional structure diagrams of peptides L18N5 and L18N6P are shown below. Figure 3 , 4 As shown, both polypeptides exhibit a three-dimensional structure with a central helical shape and two coiled ends.
[0085] 2. Synthesis of antimicrobial peptides by solid-phase chemical synthesis
[0086] The preparation of antimicrobial peptides proceeded sequentially from the C-terminus to the N-terminus using a peptide synthesizer. First, the resin was swollen by immersing Rink resin in DMF solution and shaking it at a constant speed for 40 minutes to ensure complete swelling. Next, the first Fmoc-protected amino acid was attached to the resin using 0.4 mol HBTU and 2 mol DIEA as activators. The resin was then rinsed six times (using 15 mL DMF), deprotected (15 mL of 20% piperidine deprotection solution was added to the reaction flask, reacted for 40 minutes, the waste liquid was drained, and the resin was rinsed six times with 15 mL DMF), and coupled (0.51 g of Fmoc-Gly-OH was dissolved in 5 mL DMF, 4.3 mL of 0.4 M HBTU was added, and nitrogen gas was purged for 30 minutes to thoroughly mix and activate the amino acid; 1.71 mL of DMF was added to the amino acid solution). After reacting with 2M DIEA solution under nitrogen for 5 minutes, the amino acid mixture was added to the reaction flask, shaken, and reacted under nitrogen for 70 minutes. For each subsequent amino acid grafted, the resin was washed six times, deprotected, and coupled repeatedly until the last amino acid was grafted. Finally, deprotection was performed, and the resin was repeatedly washed with DMF, methanol, and dichloromethane (15 mL of DMF, methanol, and dichloromethane were used each time, for 3 minutes each time). The peptide was then cleaved using a cleavage buffer (containing 16.3 mL TFA, 0.38 mL Tis, 0.38 mL EDT, 1.38 mL anisole thioether, 1.46 g phenol, and 1.46 mL deionized water). The peptide was repeatedly precipitated and washed with cold ether to obtain the initial product.
[0087] Reversed-phase high-performance liquid chromatography (RP-HPLC) was used to analyze and purify the primary product using a C18 column to obtain purified peptides L18N5 and L18N6P. The analytical column was 5 μm, and the preparative column was 10 μm. Two mobile phases were used in the experiment: phase A contained 99.9% deionized water and 0.1% trifluoroacetic acid, and phase B contained 99.9% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid.
[0088] The reversed-phase high-performance liquid chromatography (RP-HPLC) results of peptides L18N5 and L18N6P are as follows: Figure 5 , 6 As shown in the figure. Reversed-phase high-performance liquid chromatography results indicate that the purity of these synthetic peptides is greater than 97%.
[0089] Example 2
[0090] This embodiment measures the antibacterial activity of the antimicrobial polypeptide L18N6P prepared in Example 1. The specific process is as follows:
[0091] Determination of minimum inhibitory concentration (MIC):
[0092] *Pseudomonas aeruginosa* was cultured in LB-Broth and LB agar dishes, while *Candida albicans* was cultured in YPD Broth and YPD agar dishes. The peptide was dissolved in deionized water and then transferred to LB-Broth or YPD Broth to obtain the peptide stock solution. Subsequently, the peptide was serially diluted in LB-Broth / YPD Broth (final concentrations of 6667 μg / mL, 3333 μg / mL, 1667 μg / mL, 833 μg / mL, 417 μg / mL, 208 μg / mL, 104 μg / mL, 52 μg / mL, 26 μg / mL, and 13 μg / mL). A peptide-free LB-Broth / YPD Broth solution was prepared as a control. The concentration of the microbial suspension was adjusted to 1–5 × 10⁻⁶. 6 The concentration was CFU / mL, and 100 μL of microbial suspension was added to 11 tubes of peptides at different concentrations. The tubes were incubated at 37°C for 24 hours. The minimum MIC (micron control limit) of the tested bacteria was determined by visual inspection; the tube with the lowest drug concentration showed no bacterial growth and remained clear.
[0093] Determination of minimum bactericidal concentration (MBC):
[0094] For the minimum inhibitory concentration (MIC) determination, after visual inspection, 0.1 mL of liquid from each dilution tube showing no bacterial growth was added to a 90 mm LB-agar / YPD agar plate and spread evenly with a sterile glass rod. The control group bacterial suspension was diluted 10... 5 Then, 100 μL of the control group bacterial solution was spread on an agar plate as in the experimental group. After incubation at 37°C for 24 hours, the number of colonies on the plate was observed. The lowest drug concentration corresponding to a plate with no more than 5 colonies was the minimum bactericidal concentration of MBC.
[0095] Table 2 Results of Minimum Inhibitory Concentration and Minimum Bactericidal Concentration Tests for Peptides
[0096]
[0097] The test results of peptide MIC and MBC are shown in Table 2. As can be seen from Table 2, the designed peptides L18N5 and L18N6P both exhibited significant inhibitory effects against the two representative bacterial species. For *Pseudomonas aeruginosa*, the minimum inhibitory concentration (MIC) of L18N5 was 52 μg / mL, and the minimum bactericidal concentration (MBC) was 104 μg / mL; while the MIC and MBC of L18N6P against *Pseudomonas aeruginosa* were both 104 μg / mL. For the more drug-resistant fungus, *Candida albicans*, good inhibitory and bactericidal effects were also observed.
[0098] Due to the different testing methods for MIC and MBC, the bactericidal rates corresponding to the lowest bactericidal concentrations of the peptides for each bacterial species in this result are much higher than 99.99%.
[0099] Example 3
[0100] This embodiment measures the cytotoxicity of the antimicrobial peptide L18N6P prepared in Example 1. The specific procedure is as follows:
[0101] Human dermal fibroblasts were selected as the target for testing peptide cytotoxicity. When the cells reached approximately 80% cell growth, the culture medium was replaced with a medium containing one-fold lower limit concentration (LDC) of the peptide. Cell growth was observed after culturing at 37°C for 24 hours.
[0102] Cell viability test:
[0103] The Alamar Blue assay was used to test cell viability, specifically by testing the viability of each group of cells with Alamar Blue reagent after 24 hours. The ratio of Alamar Blue to culture medium was 1:10. After incubation at 37°C for 4 hours, the absorbance of the culture medium in each well was measured using a microplate reader. Complete culture medium without peptide solution served as the control group, and 10% DMSO solution served as the negative control group.
[0104] Figure 7 The results of Alamar Blue assay for the effects of different peptides on cell viability show that cells cultured in peptide L18N6P solution have the highest fluorescence value, even exceeding that of the control group in complete culture medium. Cells cultured in peptide L18N5 solution have a slightly lower fluorescence value than the control group in complete culture medium, but a significantly higher fluorescence value than those cultured in DMSO solution.
[0105] Cell morphology observation:
[0106] Following the Alamar Blue assay, cells were treated with a live / dead staining kit according to Invitrogen's protocol. Cells were rinsed with HBSS and then stained with the live / dead staining reagent for 15 min at room temperature. After rinsing with HBSS, cells were fixed with 4% glutaraldehyde / HBSS for 1 h. Finally, the growth and morphological changes of each group of cells were observed under a laser confocal scanning electron microscope.
[0107] Cell morphology observation results as follows Figure 8 As shown in the figure, the cell morphology after culturing with the two polypeptide solutions is almost identical to that of the control group in complete culture medium. The cells have normal extension morphology, but the cells treated with polypeptide L18N6P solution have better proliferation status, while the cells treated with polypeptide L18N5 solution have slightly fewer proliferation numbers than the control group in complete culture medium. This proves that the polypeptide L18N6P of the present invention is completely non-toxic to fibroblasts and can even promote cell growth.
[0108] The embodiments of the present invention have been described in detail above with reference to the accompanying drawings. However, the present invention is not limited to the above embodiments, and various changes can be made within the scope of knowledge possessed by those skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof can be combined with each other unless otherwise specified.
Claims
1. A polypeptide, It is characterized in that The polypeptide is selected from any one of the following (1)-(4): (1) a polypeptide having an amino acid sequence as shown in SEQ ID NO: 1; (2) a polypeptide having an amino acid sequence as shown in SEQ ID NO: 2; (3) A polypeptide having the same function as the polypeptide shown in (1) obtained by replacing, deleting or adding one or more amino acids at the N-terminus and the C-terminus of the amino acid sequence shown in SEQ ID NO: 1; (4) A polypeptide having the same function as the polypeptide shown in (2) obtained by replacing, deleting or adding one or more amino acids at the N-terminus and the C-terminus of the amino acid sequence shown in SEQ ID NO:
2.
2. Biomaterial, the biomaterial being any one of 1) to 4): 1) A nucleic acid molecule encoding the polypeptide according to claim 1; 2) An expression cassette containing the nucleic acid molecule described in 1); 3) A recombinant vector containing 1) the nucleic acid molecule or 2) the expression cassette; 4) A recombinant cell containing 1) the nucleic acid molecule, 2) the expression cassette or 3) the recombinant vector.
3. A method for preparing the polypeptide according to claim 1, It is characterized in that The preparation method comprises the following steps: using solid phase synthetic resin as a starting material and adopting a solid phase synthesis method to prepare the polypeptide.
4. Use of the polypeptide according to claim 1 or the biomaterial according to claim 2 in the preparation of antibacterial products.
5. The use according to claim 4, It is characterized in that The fungi include bacteria and fungi.
6. The use according to claim 5, It is characterized in that The bacteria include Gram-negative bacteria; Preferably, the Gram-negative bacteria include Pseudomonas aeruginosa.
7. The use according to claim 5, It is characterized in that The fungi include Candida albicans.
8. The use according to claim 4, It is characterized in that The product includes a medicine or a preparation.
9. A drug, It is characterized in that The drug comprises the polypeptide as claimed in claim 1; Preferably, the drug further comprises a pharmaceutically acceptable carrier.
10. The drug according to claim 9, It is characterized in that The dosage form of the drug includes solid, semi-solid or liquid forms, which can be aqueous solutions, non-aqueous solutions or suspensions; Preferably, the dosage form is a tablet, capsule, soft capsule, granule, pill, oral solution, dry suspension, drop pill, dry extract, injection, transdermal agent or transdermal microneedle; And / or, the administration method of the drug includes injection or oral administration.
Citation Information
Patent Citations
Polypeptide medicine for resisting pseudomonas aeruginosa and application thereof
CN117126239A
